Enable Injections Appoints David Kroekel as Chief Operating Officer USA - English USA - English
Ohio Pen/10251828

CINCINNATI, Feb. 7, 2024 ~ David Kroekel has been appointed as the new Chief Operating Officer of Enable Injections, a leading company in developing and manufacturing wearable drug delivery systems. In this critical position, Mr. Kroekel will be responsible for overseeing the ongoing engineering, manufacturing, and supply of the Company's enFuse technology.

According to Mike Hooven, Chairman and CEO of Enable Injections, "David brings a wealth of experience in cross-functional collaboration, infrastructure development, and engineering excellence in medical device manufacturing and development." He also added that Mr. Kroekel's leadership has played a pivotal role in the company's success so far.

With over 35 years of experience in medical device operations and product development, Mr. Kroekel is well-equipped to take on this new role at Enable Injections. Prior to joining the company, he served as the Biomedical Global Head of Operations at DSM Biomedical where he was responsible for global leadership of biologics and medical materials manufacturing. He also held senior positions at Flowonix Medical, Teleflex Medical, and Arrow International's EMEA business unit in Belgium.

More on Ohio Pen
Mr. Kroekel holds a Bachelor of Science in Mechanical Engineering from Pennsylvania State University and a Master of Science in Manufacturing Systems Engineering from Lehigh University.

In his new role as COO, Mr. Kroekel is excited to lead and advance how their manufacturing and product development teams can increase capabilities and efficiencies in delivering their wearable technology to more patients. He believes that enFuse is a breakthrough solution for meeting patient needs with its hands-free wearable technology that allows self-administration of large-volume medications without an IV or syringe pump.

This strategic leadership reinforcement comes after the recent U.S. FDA approval and launch of Enable's first enFuse combination product. The company is currently working with several pharmaceutical partners to conduct clinical trials and plan for joint commercial launch of their therapies using enFuse technology.

Enable continues to selectively add to its list of pharmaceutical partners, with indications and patient populations who will benefit from the enFuse system. With Mr. Kroekel's expertise and leadership, the company is poised for long-term commercial success and increasing product demand. The team at Enable is committed to driving innovation for enFuse and bringing this game-changing technology to their partners, healthcare professionals, and most importantly – patients.
Filed Under: Business

Show All News | Report Violation


Latest on Ohio Pen